Rheumatoid ArthritisPhase 2NCT01373151
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
A Phase 2 study testing BMS-945429 and Methotrexate in people with Rheumatoid Arthritis, run by CSL Behring at 100 sites in 19 countries.
Trial summary
The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- BMS-945429 and Methotrexate
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 418 participants
- Where
- 100 sitesin 19 countries
- Study dates
- Jun 2011to Jun 2015
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Inadequate response to Methotrexate
- Must have been taking Methotrexate for at least 3 months at a minimal weekly dose of at least 15 mg and stable dose for 4 weeks prior to randomization
- American College of Rheumatology (ACR) global function status class 1-3
- Minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand or wrist
- High sensitivity C-reactive protein (hsCRP) ≥ 0.8 mg/dL
Who cannot join
- Previously received or currently receiving concomitant biologic therapy
Trial locations and contacts
100 sites in 19 countries.
100 sites in 19 countries
Japan14 sites
Local Institution
Bunkyo-ku, Tokyo, 1138519
Local Institution
Chiba, Chiba, 2608712
Local Institution
Higashi-hiroshima-shi, Hiroshima, 7390002
Local Institution
Kato-shi, Hyōgo, 6731462
Local Institution
Kitakyushu-shi, Fukuoka, 8078555
Local Institution
Miyazaki, Miyazaki, 8800122
Local Institution
Nagano, Nagano, 3808582
Local Institution
Nagasaki, Nagasaki, 8528501
Local Institution
Osaka, Osaka, 5458586
Local Institution
Sasebo-shi, Nagasaki, 8571195
Local Institution
Shinjuku-Ku, Tokyo, 1608582
Local Institution
Shizuoka, Shizuoka, 4208623
Local Institution
Tomigusuku-shi, Okinawa, 9010243
Local Institution
Toshima-ku, Tokyo, 1708476
United States13 sites
East Penn Rheumatology Associates, P.C.
Bethlehem, Pennsylvania, 18015
Box Arthritis And Rheumatology Of The Carolinas, Pllc
Charlotte, North Carolina, 28210
Altoona Center For Clinical Research
Duncansville, Pennsylvania, 16635
Arthritis Associates Of Mississippi
Jackson, Mississippi, 39202
Physician Research Collaboration, Llc
Lincoln, Nebraska, 68516
Health Research Of Oklahoma
Oklahoma City, Oklahoma, 73103
Sun Valley Arthritis Center, Ltd.
Peoria, Arizona, 85381
Quincy Medical Group
Quincy, Illinois, 62301
Rockford Orthopedic Associates, Llc.
Rockford, Illinois, 61107
San Diego Arthritis Medical Clinic
San Diego, California, 92108
Seattle Rheumatology Associates
Seattle, Washington, 98104
New England Research Associates, Llc
Trumbull, Connecticut, 06611
Clinical Pharmacology Study Group
Worcester, Massachusetts, 01605
Argentina8 sites
Local Institution
Capital Federal, Buenos Aires, 1015
Local Institution
Capital Federal, Buenos Aires, 1425
Local Institution
Capital Federal, Buenos Aires, 1428
Local Institution
Capital Federal, Buenos Aires, 1431
Local Institution
Córdoba, 5000
Local Institution
Rosario, Santa Fe Province, 2000
Local Institution
San Juan, 5400
Local Institution
San Miguel de Tucumán, Tucumán Province, 4000
Brazil7 sites
Local Institution
Curitiba, Paraná, 80060
Local Institution
Curitiba, Paraná, 80440
Local Institution
Goiânia, Goiás, 74110
Local Institution
Juiz de Fora, Minas Gerais, 36010
Local Institution
Porto Alegre, Rio Grande do Sul, 91610
Local Institution
São Paulo, 04032
Local Institution
São Paulo, 04266
Mexico7 sites
Local Institution
Culiacán, Sinaloa, 80230
Local Institution
Guadalajara, Jalisco, 42650
Local Institution
Guadalajara, Jalisco, 45040
Local Institution
Mexico City, Mexico City, 11850
Local Institution
Monterrey, Nuevo León, 64020
Local Institution
Morelia, Michioacan, 58270
Local Institution
San Luis Potosí City, 78213
Russia6 sites
Local Institution
Kazan', 420064
Local Institution
Moscow, 115522
Local Institution
Novosibirsk, 630005
Local Institution
Saint Petersburg, 191014
Local Institution
Yaroslavl, 150003
Local Institution
Yekaterinburg, 620102
South Africa6 sites
Local Institution
Durban, KwaZulu-Natal, 4001
Local Institution
Panorama, Western Cape, 7500
Local Institution
Pinelands, Cape Town, Western Cape, 7405
Local Institution
Pretoria, Gauteng, 0083
Local Institution
Pretoria, Gauteng, 0132
Local Institution
Tygerberg, Western Cape, 7505
Poland5 sites
Local Institution
Katowice, 40-748
Local Institution
Krakow, 31-531
Local Institution
Poznan, 60773
Local Institution
Warsaw, 01-868
Local Institution
Warsaw, 02-118
Spain5 sites
Local Institution
A Coruña, 15006
Local Institution
Madrid, 28040
Local Institution
Santander, 39008
Local Institution
Santiago de Compostela, 15706
Local Institution
Seville, 41071
Germany4 sites
Local Institution
Berlin, 14059
Local Institution
Cologne, 50931
Local Institution
Leipzig, 04103
Local Institution
Würzburg, 97080
Hungary4 sites
Local Institution
Budapest, 1027
Local Institution
Debrecen, 4012
Local Institution
Gyula, 5700
Local Institution
Veszprém, 8200
Taiwan4 sites
Local Institution
Changhua, 500
Local Institution
Kaohsiung City, 833
Local Institution
Taichung, 404
Local Institution
Taoyuan, 333
Canada3 sites
Local Institution
Montreal, Quebec, H2L 1S6
Local Institution
Québec, Quebec, G1W 4R4
Centre De Recherche Musculo-Squelettique
Trois-Rivières, Quebec, G8Z 1Y2
France3 sites
Local Institution
Bordeaux, 33076
Local Institution
Chambray-lès-Tours, 37170
Local Institution
Strasbourg, 67098
Italy3 sites
Local Institution
Naples, 80131
Local Institution
Padova, 35128
Local Institution
Reggio Emilia, 42100
South Korea3 sites
Local Institution
Daegu, 705-718
Local Institution
Seoul, 133-792
Local Institution
Seoul, 137-701
Belgium2 sites
Local Institution
Brussels, 1200
Local Institution
Hasselt, 3500
Czechia2 sites
Local Institution
Prague, 128 50
Local Institution
Prague, 140 59
About this study
Official title: A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.
- Conditions
- Rheumatoid Arthritis
- Being tested
- BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BMS-945429 PlaceboDrug
Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
BMS-945429Biological
Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
BMS-945429Biological
Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
BMS-945429Biological
Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
BMS-945429Biological
Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
MethotrexateDrug
Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
MethotrexateDrug
Tablets, Oral, 15 mg, Weekly, 48 weeks
Methotrexate PlaceboDrug
Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
MethotrexateDrug
Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
Adalimumab PlaceboDrug
Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
AdalimumabDrug
Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Placebo comparator | BMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo Receives: Drug: BMS-945429 Placebo; Biological: BMS-945429; Drug: Methotrexate; Drug: Adalimumab Placebo |
| Arm 2 | Experimental | BMS-945429 + Methotrexate + Adalimumab Placebo Receives: Biological: BMS-945429; Drug: Methotrexate; Drug: Adalimumab Placebo |
| Arm 3 | Experimental | BMS-945429 + Methotrexate + Adalimumab Placebo Receives: Biological: BMS-945429; Drug: Methotrexate; Drug: Adalimumab Placebo |
| Arm 4 | Experimental | BMS-945429 + Methotrexate + Adalimumab Placebo Receives: Biological: BMS-945429; Drug: Methotrexate; Drug: Adalimumab Placebo |
| Arm 5 | Experimental | BMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo Receives: Biological: BMS-945429; Drug: Methotrexate Placebo; Drug: Methotrexate; Drug: Adalimumab Placebo |
| Arm 6 | Experimental | BMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo Receives: Biological: BMS-945429; Drug: Methotrexate Placebo; Drug: Methotrexate; Drug: Adalimumab Placebo |
| Arm 7 | Active comparator | Adalimumab + Methotrexate Receives: Drug: Methotrexate; Drug: Adalimumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Measured: At 12 Weeks
Secondary outcomes (16)
Percent of Participants With ACR 20 Response
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Measured: At 24 weeks
Percent of Participants Achieving ACR 50 Response Rate
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Measured: At weeks 12 and 24
Percent of Participants Achieving ACR 70 Response Rate
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Measured: At weeks 12 and 24
Mean Change From Baseline in Disease Activity as Measured by Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.
Measured: Baseline, weeks 12 and 24
Percent of Participants With Remission by DAS28-CRP
DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.
Measured: At weeks 12 and 24
Mean Change From Baseline in Clinical Disease Activity Index (CDAI)
CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76.
CDAI <= 2.8 = Remission CDAI > 2.8 and <= 10 = Low Disease Activity CDAI > 10 and <= 22 = Moderate Disease Activity CDAI > 22 = High Disease Activity
Measured: Baseline, weeks 12 and 24
Percent of Participants With Remission by CDAI
CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76.
CDAI <= 2.8 = Remission CDAI > 2.8 and <= 10 = Low Disease Activity CDAI > 10 and <= 22 = Moderate Disease Activity CDAI > 22 = High Disease Activity
Measured: At weeks 12 and 24
Mean Change From Baseline in Simplified Disease Activity Index (SDAI)
SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86.
0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity
Measured: Baseline, weeks 12 and 24
Percent of Participants With Remission by SDAI
SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86.
0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity
Measured: At weeks 12 and 24
Percent of Participants With Remission Rate by Boolean Definition
Boolean-based definition:
At any time point, a patient must satisfy all of the following:
TJC ≤1 (0-28) SJC ≤1 (0-28) CRP ≤1 mg/dl Patient Global Assessment ≤1 (on a 0-10 scale)
Measured: At weeks 12 and 24
Mean Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index
Patients report the amount of difficulty they have in performing 8 categories. Each category is scored on a scale ranging from 0 (performed without any difficulty) to 3 (cannot be done at all). The HAQ-DI is then calculated by summing the scores and dividing by the number of categories answered. Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. The HAQ-DI cannot be calculated if the subject does not have scores for at least 6 categories. A response was defined as a subject with a reduction from baseline in HAQ-DI of at least 0.22.
Measured: Baseline, weeks 12 and 24
Mean Change From Baseline in Short Form 36 (SF-36) as Measured by Physical and Mental Components
The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.
Measured: Baseline, weeks 12 and 24
Mean Change From Baseline in Fatigue Severity (VAS) Score
A 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity according to a self-report scale. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.
Measured: Baseline, weeks 12 and 24
Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
The WPAI yeilds four types of scores:
- Absenteeism (work time missed)
- Presenteesism (impairment at work / reduced on-the-job effectiveness)
- Work productivty loss (overall work impairment / absenteeism plus presenteeism)
- Activity Impairment WPAI outcomes are expressed as impairment percentages with each subscale score ranging from 0-100. The subscale scores are added and averaged to produce a total WPAI score between 0-100. Higher scores indicate greater impairment and less productivity.
Measured: Baseline, weeks 12 and 24
Mean Change From Baseline in Radiographic (MRI) Progression of Synovitis, Osteitis (Bone Marrow Edema), Bone Erosion and Cartilage Loss (Joint-space Narrowing)
Measured: Baseline and week 12
Mean Change From Baseline in Radiographic (X-ray) Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijde Total Score
The Sharp-van der Heijde total score ranges from 0-528. Scores for erosion range from 0 to 5 in the hands and 0 to 10 in the feet and reflect erosion size, with 0 defined as no erosion and 3 defined as a large erosion passing the midline of the joint. If there is > 1 erosion per joint, scores can be combined to give a maximum score of 5 per joint in the hands and 10 per joint in the feet (a maximum of 5 at each side of the joint). Joint space narrowing scores vary from 0 to 4 in both the hands and feet, with 0 being normal and 4 being the absence of joint space with evident ankylosis or subluxation. Gross osteolysis and pencil-in-cup change are scored separately and, if present, are assigned the maximum score for erosion and joint space narrowing for the same affected joint. Higher scores indicate increased joint damage.
Measured: Baseline and week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2011 (estimated)
- Study startJun 2011
- Primary completionSep 2012
- Study completionJun 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by CSL BehringThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 418 participants (actual)
Sponsor and investigators
- Lead sponsor
- CSL Behring
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01373151
- Sponsor's protocol ID
- IM133-001
- Other IDs
- 2010-023956-99
- Status last verified
- Nov 2021
- First submitted
- 13 Jun 2011
- Last updated
- 6 Dec 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol. 2015 Oct;67(10):2591-600. doi: 10.1002/art.39249.
PubMed 26138593
Study at a glance
From the registry record, last updated by the sponsor on 6 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
- ClinicalTrials.gov ID
- NCT01373151
- Acronym / sponsor ID
- IM133-001
- Conditions
- Rheumatoid Arthritis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 418 participants (actual)
- Lead sponsor
- CSL BehringIndustry (pharma, biotech, devices)
- Study start
- Jun 2011
- Primary completion
- Sep 2012 (actual)
- Study completion
- Jun 2015 (actual)
- First posted
- 14 Jun 2011 (estimated)
- Results
- Posted 6 Dec 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 7
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Placebo comparator | Drug: BMS-945429 Placebo, Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab PlaceboBMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo |
| Arm 2 | Experimental | Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab PlaceboBMS-945429 + Methotrexate + Adalimumab Placebo |
| Arm 3 | Experimental | Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab PlaceboBMS-945429 + Methotrexate + Adalimumab Placebo |
| Arm 4 | Experimental | Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab PlaceboBMS-945429 + Methotrexate + Adalimumab Placebo |
| Arm 5 | Experimental | Biological: BMS-945429, Drug: Methotrexate Placebo, Drug: Methotrexate, Drug: Adalimumab PlaceboBMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo |
| Arm 6 | Experimental | Biological: BMS-945429, Drug: Methotrexate Placebo, Drug: Methotrexate, Drug: Adalimumab PlaceboBMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo |
| Arm 7 | Active comparator | Drug: Methotrexate, Drug: AdalimumabAdalimumab + Methotrexate |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Inadequate response to Methotrexate
- Must have been taking Methotrexate for at least 3 months at a minimal weekly dose of at least 15 mg and stable dose for 4 weeks prior to randomization
- American College of Rheumatology (ACR) global function status class 1-3
- Minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand or wrist
- High sensitivity C-reactive protein (hsCRP) ≥ 0.8 mg/dL
Key exclusion criteria (1 listed)
- Previously received or currently receiving concomitant biologic therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BMS-945429 PlaceboInjection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only | Drug | Arm 1 |
| BMS-945429Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only | Biological | Arm 4 |
| BMS-945429Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks | Biological | Arm 3, Arm 6 |
| BMS-945429Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48 | Biological | Arm 1, Arm 4 |
| BMS-945429Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks | Biological | Arm 2, Arm 5 |
| MethotrexateTablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only | Drug | Arm 1 |
| MethotrexateTablets, Oral, 15 mg, Weekly, 48 weeks | Drug | Arm 2, Arm 3, Arm 4, Arm 7 |
| Methotrexate PlaceboTablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only | Drug | Arm 5, Arm 6 |
| MethotrexateTablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only | Drug | Arm 5, Arm 6 |
| Adalimumab PlaceboInjection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks | Drug | Arm 1, Arm 2, Arm 3, Arm 4, Arm 5, Arm 6 |
| AdalimumabInjection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks | Drug | Arm 7 |
Primary outcome
Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate
Time frame: At 12 Weeks
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
16 secondary outcomes
Percent of Participants With ACR 20 Response
Time frame: At 24 weeks
Percent of Participants Achieving ACR 50 Response Rate
Time frame: At weeks 12 and 24
Percent of Participants Achieving ACR 70 Response Rate
Time frame: At weeks 12 and 24
Mean Change From Baseline in Disease Activity as Measured by Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
Time frame: Baseline, weeks 12 and 24
Percent of Participants With Remission by DAS28-CRP
Time frame: At weeks 12 and 24
Mean Change From Baseline in Clinical Disease Activity Index (CDAI)
Time frame: Baseline, weeks 12 and 24
Percent of Participants With Remission by CDAI
Time frame: At weeks 12 and 24
Mean Change From Baseline in Simplified Disease Activity Index (SDAI)
Time frame: Baseline, weeks 12 and 24
Percent of Participants With Remission by SDAI
Time frame: At weeks 12 and 24
Percent of Participants With Remission Rate by Boolean Definition
Time frame: At weeks 12 and 24
Mean Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index
Time frame: Baseline, weeks 12 and 24
Mean Change From Baseline in Short Form 36 (SF-36) as Measured by Physical and Mental Components
Time frame: Baseline, weeks 12 and 24
Mean Change From Baseline in Fatigue Severity (VAS) Score
Time frame: Baseline, weeks 12 and 24
Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
Time frame: Baseline, weeks 12 and 24
Mean Change From Baseline in Radiographic (MRI) Progression of Synovitis, Osteitis (Bone Marrow Edema), Bone Erosion and Cartilage Loss (Joint-space Narrowing)
Time frame: Baseline and week 12
Mean Change From Baseline in Radiographic (X-ray) Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijde Total Score
Time frame: Baseline and week 24
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Dec 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 26138593Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol. 2015 Oct;67(10):2591-600. doi: 10.1002/art.39249.
Related trials for Rheumatoid Arthritis
Not yet recruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
Active, not recruitingObservational study
Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries
Rheumatoid Arthritis, Ankylosing Spondylitis
RecruitingPhase 2
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
Sjögren's Syndrome
RecruitingObservational study
Characterization of Diseases With Salivary Gland Involvement
Healthy Volunteer, Sjogren's Syndrome
Not yet recruitingPhase 2
A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)
Rheumatoid Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol-Myers Squibb study director
Bristol-Myers Squibb
100 sites in 19 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing BMS-945429 and Methotrexate in people with Rheumatoid Arthritis, run by CSL Behring at 100 sites in 19 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 100 sites in Japan, United States, Argentina, Brazil, Mexico and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 6 Dec 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate (time frame: At 12 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01373151, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Dec 2021.